Although the mortality rate from lung cancer is decreasing over the years, the identification of “druggable” oncogenes (such as EGFR, ALK) provides the opportunity for the study and implementation of effective targeted therapy [167]. The gene discussed is EGFR; the disease is lung carcinoma.